A Biotech Stock With High FDA Approval Odds For A Rare Disorder In November, However...

A biotech stock with strong FDA approval odds this November may see limited upside amid a full valuation and a pending lawsuit.

Biotech stocks are coming back. Here's what's driving the sector higher.

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

UniQure stock crashes over 50% today after FDA says Huntington’s therapy data isn’t enough - here's what investors need to know

UniQure NV's stock plummeted over 54% after the FDA deemed the clinical data for its Huntington's disease gene therapy AMT-130 inadequate. Investors are left questioning the future of the therapy and ...

Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%

Now, it’s worth noting Stock Advisor's total average return is 1,072% — a market-crushing outperformance compared to 194% for the S&P 500. Don’t miss out on the latest top 10 list, available when you ...

I Think These Are the 2 Best AI Stocks to Buy in November

The AI infrastructure buildout has moved from speculation to reality, and two companies are positioned to capture the lion's share of spending.

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is 'growing substantially'

Rigel Pharmaceuticals has landed on CNBC's list of top performing stocks of companies located in San Francisco.